View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 7, 2022

PathMaker begins MyoRegulator trial to treat post-stroke spasticity

The trial will assess the safety and efficacy of post-stroke lower-limb spasticity treatment with MyoRegulator.

PathMaker Neurosystems has commenced the multi-centre clinical trial of MyoRegulator for the non-invasive treatment of post-stroke spasticity in the US.

The non-invasive neuromodulation device is designed to suppress hyperexcitable spinal motor neurons.

It uses the company’s DoubleStim technology, which enables simultaneous stimulation at spinal and peripheral sites.

The randomised, sham-controlled, multi-centre, double-blind clinical trial is designed to assess the safety and efficacy of post-stroke lower-limb spasticity treatment with MyoRegulator in sham-treated and active participants.

It is being conducted with the Spaulding Rehabilitation Hospital in Charlestown, Massachusetts, and is expected to recruit 76 subjects.

The National Institute of Neurological Disorders and Stroke (NINDS) is providing a $4.9m NINDS Cooperative Research to Enable and Advance Translational Enterprises for Devices (CREATE Devices) grant for the pivotal clinical study.

PathMaker CEO and president Nader Yaghoubi said: “The launch of this multi-centre trial is an important milestone in the development of our first-in-class product, MyoRegulator.

“We are very pleased to be working with the world-class team at Spaulding, and are grateful to have the support of NINDS as we advance this product towards commercial launch.”

MyoRegulator is claimed to be the first and only neuromodulation device developed to treat muscle spasticity without using drugs or surgery.

It has been designated as a breakthrough medical device by the US Food and Drug Administration (FDA) and used in two completed clinical trials conducted in Europe and the US.

In 2019, PathMaker announced positive data from a clinical trial of the MyoRegulator device for the treatment of upper extremity spasticity in chronic stroke patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network